AlphAIAlphAI — Financial news for AI agents
manilatimes.netJUL 152 min read$AMRN

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Amarin Corporation plc (NASDAQ: AMRN) said it will release its Q2 2026 financial results in a pre-market press release and hold a conference call on July 29, 2026 at 8:00 a.m. ET. The company provided dial-in and webcast details, plus replay access through Jan. 29, 2027.

Original reporting
manilatimes.net
Published Jul 15, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 — source image
Source · manilatimes.net
Decision brief

The 30-second read

$AMRNNeutralMed
01

Why it matters

The primary tradable element is event timing for earnings volatility and potential guidance surprises.

02

Market read

Provides the exact pre-market release and call time, which can drive near-term positioning and hedging decisions for AMRN.

03

What to watch

Any meaningful price reaction will hinge on Q2 revenue, margins, and forward guidance, none of which are included in this announcement.

Relevance 4/10Novelty 5/10Timing: Ahead of the July 29, 2026 pre-market Q2 2026 results and 8:00 a.m. ET call.

Background

Amarin is a cardiovascular therapeutics company; this notice is a standard earnings calendar update for Q2 2026.

Company-level read

Ticker impact

$AMRNNeutralMedium confidence
Context

Amarin announced it will report Q2 2026 results pre-market and hold a conference call July 29, 2026 at 8:00 a.m. ET.

Expected impact

Likely elevated volatility into the July 29 pre-market release; direction depends on Q2 results and guidance details not provided here.

Evidence & confidence

The article discloses only the reporting date and call time, with no financial figures, guidance, or operational updates.

Market effects

Sector

Limited, since it is a single-company earnings scheduling notice with no sector-wide datapoints.

Regional

Minimal, as the event is company-specific and not tied to a regional macro/regulatory change.

Global

Low, no international regulatory or product development updates are disclosed.

Counterpoint

What could challenge this read

Because the release details contain no numbers or guidance, traders may treat this as routine and focus on options-implied volatility rather than directional conviction.

Key entities

  • company
    Amarin Corporation plc

    NASDAQ-listed cardiovascular therapeutics company scheduling Q2 2026 results and an investor call.

  • event_date
    July 29, 2026

    Date of the pre-market Q2 2026 financial results release and 8:00 a.m. ET conference call.

Read at source← All news

Related articles

OCT 25
$AMRNMedAI 8/10

Amarin’s icosapent ethyl shows survival benefit in cancer trial

Amarin Corporation (NASDAQ:AMRN) reported Phase 3 trial results for icosapent ethyl in colorectal cancer liver metastases. The primary endpoint of progression-free survival was not met, but the key secondary endpoint of overall survival showed a statistically significant benefit. The five-year overall survival estimate was 62.0% with icosapent ethyl versus 45.1% with placebo. The drug was found to be safe and well tolerated.

investing.com2 min
OCT 25
$AMRNMedAI 8/10

A colorectal cancer trial missed its goal, but estimated 5-year survival was 62% with the drug versus 45% with placebo.

Amarin's drug VASCEPA failed to meet its primary endpoint in a colorectal cancer trial but showed a 5-year survival rate of 62% vs. 45% with placebo. The study, sponsored by the University of Leeds, found improved overall survival but not progression-free survival. Amarin plans further evaluation, citing potential long-term value.

stocktitan.net2 min
AUG 8
$AMRNMed

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.

fool.com7 min
JUL 29
$AMRNMed

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading…

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash

SEC EDGAR 8-K6 min